High costs and burden of illness in acute rhinosinusitis: real-life treatment patterns and outcomes in Swedish primary care
2012 (English)In: Primary Care Respiratory Journal, ISSN 1471-4418, E-ISSN 1475-1534, Vol. 21, no 2, 174-179 p.Article in journal (Refereed) Published
BACKGROUND: Few studies have investigated the impact of acute rhinosinusitis on disease-specific quality of life, and disease costs have not been studied previously in Scandinavia. AIMS: To study symptoms, treatment patterns, quality of life and costs in adults with acute rhinosinusitis. METHODS: This was an observational study in primary care. Patients aged 18–80 years seeking care for acute rhinosinusitis were evaluated using the Major Symptom Score (MSS) on days 0 and 15. Recommended and used treatments, quality of life and costs were assessed by questionnaires including EQ-5D™ and a visual analogue scale (VAS) on the same days. RESULTS: 150 patients were enrolled; 143 provided follow-up data. The proportion of MSS responders was 91%. Mean MSS decreased from 8.4 on day 0 (N=150) to 1.9 on day 15 (N=143). Patients reporting pain/discomfort and problems with usual activities decreased from 88.4% to 31.5% and from 43.2% to 1.4%, respectively, and mean VAS increased from 58.7 to 79.5. Intranasal corticosteroids were the most recommended and/or prescribed drugs. Total cost for an episode was 10,260 SEK (€1,102), of which 75% were indirect costs. CONCLUSIONS: With treatment dominated by intranasal corticosteroids, a high proportion of responders and good symptom relief were seen. Acute rhinosinusitis seems to cause a high burden on quality of life and also a high cost for society.
Place, publisher, year, edition, pages
2012. Vol. 21, no 2, 174-179 p.
IdentifiersURN: urn:nbn:se:uu:diva-170782DOI: 10.4104/pcrj.2012.00011PubMedID: 22349918OAI: oai:DiVA.org:uu-170782DiVA: diva2:509494